Arandomized phase 3 trial of thalidomide and prednisone as maintenance therapy afterASCT in patients withMMwith a quality-of-life assessment: The national cancer Institute of Canada clinicals trials group myeloma 10 trial

Blood

Volumn 121, Issue 9, 2013, Pages 1517-1523

  Stewart, A Keith ^a   Trudel, Suzanne ^b   Bahlis, Nizar J ^c   White, Darrell ^d   Sabry, Waleed ^e   Belch, Andrew ^f   Reiman, Tony ^g   Roy, Jean ^h   Shustik, Chaim ⁱ   Kovacs, Michael J ^j   Rubinger, Morel ^k   Cantin, Guy ^l   Song, Kevin ^m   Tompkins, Kirsty A ⁿ   Marcellus, Deb C ^o   Lacy, Martha Q ^p   Sussman, Jonathan ^q   Reece, Donna ^b   Brundage, Michael ^q   Harnett, Erica L ^r   Shepherd, Lois ^r   Chapman, Judy Anne W ^r   Meyer, Ralph M ^r   more..

^a MAYO CLINIC   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c TOM BAKER CANCER CENTRE   (Canada)

^d QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^e Saskatoon Cancer Center   (Canada)

^f CROSS CANCER INSTITUTE   (Canada)

^g SAINT JOHN REGIONAL HOSPITAL   (Canada)

^h MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

ⁱ MCGILL UNIVERSITY   (Canada)

^j LONDON HEALTH SCIENCES CENTRE   (Canada)

^k CANCERCARE MANITOBA   (Canada)

^l LAVAL UNIVERSITY   (Canada)

^m BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁿ Dr H Bliss Murphy Cancer Clinic   (Canada)

^o JURAVINSKI CANCER CENTRE   (Canada)

^p MAYO CLINIC   (United States)

^q Cancer Centre of Southeastern Ontario   (Canada)

^r National Cancer Institute of Canada Clinical Trials Group   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; PREDNISONE; THALIDOMIDE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AMNESIA; ANXIETY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BALANCE DISORDER; CANADA; CANCER CONTROL; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CATARACT; COGNITION; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DYSPNEA; EDEMA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; LEG SWELLING; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RECURRENT DISEASE; SENSORY NEUROPATHY; SIDE EFFECT; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; THIRST; THROMBOEMBOLISM; TREMOR; VENOUS THROMBOEMBOLISM; XEROSTOMIA; AUTOTRANSPLANTATION; CONTROLLED CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MAINTENANCE CHEMOTHERAPY; METHODOLOGY; MIDDLE AGED; MORTALITY; ONCOLOGY; ORGANIZATION; ORGANIZATION AND MANAGEMENT; SURVIVAL; TREATMENT OUTCOME;

ACADEMIES AND INSTITUTES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANADA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISONE; QUALITY OF LIFE; SURVIVAL ANALYSIS; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84876494741     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-451872     Document Type: Article

References (28)

1. Brenner H, Gondos A, Pulte D. Recent major improvement in long-Term survival of younger patients with multiple myeloma. Blood. 2008;111(5): 2521-2526.
2. Brenner H, Gondos A, Pulte D. Expected longterm survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica. 2009; 94(2):270-275.
3. Moreau P, vet-Loiseau H, Harousseau JL, Attal M. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol. 2011;29(14):1898-1906.
4. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006; 108(10):3289-3294.
5. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol. 2009;27(11):1788-1793.
6. Lokhorst HM, van der Holt B, Zweegman S, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2010;115(6):1113-1120.
7. Barlogie B, Pineda-Roman M, van Rhee F, et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008;112(8):3115-3121.
8. Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-Analysis. Blood. 2012;119(1):7-15.
9. Stewart AK, Chen CI, Howson-Jan K, et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res. 2004;10(24):8170-8176. (Pubitemid 40053375)
10. National Cancer Institute Cancer Therapy Evaluation Program. National Cancer Institute Common Toxicity Criteria (v2.0). Bethesda, MD: National Institutes of Health; 1999. http://ctep. cancer.gov/protocolDevelopment/ electronic-Applications/ctc.html. Accessed July 2, 2012.
11. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by highdose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102(5):1115-1123. (Pubitemid 28435189)
12. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-376. (Pubitemid 23073154)
13. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc. 1958;53(282):457-481.
14. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
15. Gehan EA. A Generalized Wilcoxon Test for Comparing Arbitrarily Singly-Censored Samples. Biometrika. 1965;52(1/2):203-223.
16. Lan KKG, Demets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983; 70(3):659-663.
17. Fisher RA. The logic of inductive inference. J Royal Stat Soc. 1935;98:39-54.
18. Au HJ, Ringash J, Brundage M, Palmer M, Richardson H, Meyer RM. Added value of healthrelated quality of life measurement in cancer clinical trials: the experience of the NCIC-CTG. Expert Rev Pharmacoecon Outcomes Res. 2010; 10(2):119-128.
19. KvamAK, Fayers P, Hjermstad M, Gulbrandsen N, Wisloff F. Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. Eur J Haematol. 2009; 83(4):279-289.
20. Segeren CM, Sonneveld P, van der Holt B, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood. 2003;101(6): 2144-2151. (Pubitemid 36302050)
21. Wisloff F, Hjorth M, Kaasa S, Westin J. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan and prednisone to melphalan, prednisone-And alpha interferon. Br J Haematol. 1996;94(2):324-332. (Pubitemid 26247991)
22. Westin J, Rodjer S, Turesson I, et al. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Br J Haematol. 1995;89(3):561-568.
23. Verelst S, Termorshuizen F, Uyl-de Groot C, et al. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Ann Hematol. 2011;90(12):1427-1439.
24. Wijermans P, Schaafsma M, Termorshuizen F, et al Dutch-Belgium Cooperative Group HOVON. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol. 2010;28(19): 3160-3166.
25. Attal M, Lauwers Vc, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19): 1782-91.
26. Palumbo A, Hajek R, Delforge M, et al; Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19): 1759-69.
27. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19): 1770-81.
28. Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood. 2011;118(12):3205-3211.